Results 11 to 20 of about 626,377 (227)
Swiss Medical Weekly, 2015 The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces LDL receptor recycling, leading to a decrease of low-density lipoprotein cholesterol (LDL-
Baris Gencer +2 more
doaj +9 more sources
Naturally Occurring PCSK9 Inhibitors [PDF]
Nutrients, 2020 Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events.
Adorni, Maria Pia +9 more
core +7 more sources
PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center [PDF]
Рациональная фармакотерапия в кардиологии, 2022 Aim. To characterize patients receiving PCSK9 inhibitors, and assess the efficiency of their treatment in a specialized lipid center.Material and methods.
A. V. Blokhina +5 more
doaj +2 more sources
Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. [PDF]
PLoS ONE, 2017 The introduction of Proprotein covertase subtilisin/kexin type 9 (PCSK9) inhibitors has been heralded as a major advancement in reducing low-density lipoprotein cholesterol levels by nearly 50%.
Alejandro Arrieta +3 more
doaj +3 more sources
Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence
PharmacyEmerging evidence suggested a potential link between lipid-lowering therapies and neurocognitive effects, raising concerns regarding the possible adverse impact of PCSK9 inhibitors on memory loss.
Xuezhong Shi +7 more
doaj +2 more sources
PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
PharmaceuticalsThis paper investigates the therapeutic use of PCSK9 inhibitors, particularly Evolocumab, as monoclonal antibodies for the treatment of atherosclerosis based on recent literature reviews.
Maram H. Abduljabbar
doaj +2 more sources
Cell, 2016 Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Pradeep, Natarajan, Sekar, Kathiresan
+6 more sources
Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome [PDF]
Инновационная медицина КубаниProprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in the regulation of blood cholesterol levels by binding to low-density lipoprotein receptors and promoting their degradation. Pivotal studies have shown that PCSK9 inhibition by
A. M. Namitokov +2 more
doaj +2 more sources
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Vascular Health and Risk Management, 2016 Dirk J Blom,1 Ricardo Dent,2 Rita C Castro,2 Peter P Toth3,4 1Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa; 2Amgen, Inc., Thousand Oaks, CA, 3Ciccarone Center for the Prevention of Cardiovascular ...
Blom DJ, Dent R, Castro RC, Toth PP
doaj +1 more source
PCSK9 inhibitors for hypercholesterolaemia [PDF]
BMJ, 2017 New drugs, old problems Statins (hydroxymethyl-glutaryl coenzyme A reductase inhibitors) reduce “bad” low density lipoprotein (LDL) cholesterol concentrations and cardiovascular risk. So too, do better diet and more exercise, which together almost halve rates of coronary event rates when compared with an “unfavourable lifestyle.”3 For some people ...
Patricia, McGettigan, Robin E, Ferner
openaire +2 more sources